Skip to main content
    B

    BioCryst Pharmaceuticals Inc (BCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $7.45
    -0.16 (-2.10%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BioCryst Pharmaceuticals Inc (BCRX) Government Contracts

    Updated Aug 4, 2026. Contract data from federal award records.

    Federal agencies obligated $36,032 to BioCryst Pharmaceuticals over the 12 months through Jul 31, 2026. That is less than 1% of its revenue. Department of Veterans Affairs was its only awarding agency.

    Federal Obligations

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated.

    Obligations
    $36,032
    Obligations to revenue
    0.0%
    Prior 12 months-$26.87M
    Contracts with activity8
    New contracts3
    Top agencyDepartment of Veterans Affairs
    Top agency share100.0%
    Agencies1
    Average remaining term1.8 months

    12 months through Jul 31, 2026

    Largest New Awards

    The 3 largest new awards total $541,758, and the largest makes up 66.5% of that.

    Award IDAgencyAmountStartEndDescription
    36C26026F0006Department of Veterans Affairs$360,000Oct 1, 2025Sep 30, 2026PHARM - ORLADEYO
    36C26026F0294Department of Veterans Affairs$151,465May 19, 2026Sep 30, 2026ORLADEYO 150MG CAP
    36C24926F0152Department of Veterans Affairs$30,293May 21, 2026Jun 10, 2026EMERGENCY ORLADEYO
    New federal contracts awarded in the 12 months through Jul 31, 2026, largest first. All from the Department of Veterans Affairs.

    Monthly Obligations

    The latest complete month, Apr 2026, had no net obligations. The largest month in the table was Sep 2024, at $14.25M, the last month of the federal fiscal year.

    MonthObligations
    Jul 2026$0
    Jun 2026$0
    May 2026$181,758
    Apr 2026$0
    Mar 2026-$352,893
    Feb 2026-$182,240
    Jan 2026$0
    Dec 2025$0
    Nov 2025$0
    Oct 2025$360,000
    Sep 2025$0
    Aug 2025$29,408
    MonthObligations
    Jul 2025$4,723
    Jun 2025$382,301
    May 2025$0
    Apr 2025$0
    Mar 2025$0
    Feb 2025$11,575
    Jan 2025-$301,176
    Dec 2024-$29.62M
    Nov 2024$355,799
    Oct 2024$345,808
    Sep 2024$14.25M
    Aug 2024-$12.30M

    Net obligations recorded each month, newest first. Agencies report contract actions with a delay (the Defense Department about 90 days), so the latest months, May to Jul 2026, are still incomplete and the 12-month total usually rises as agencies report the rest.

    Frequently Asked Questions About BCRX

    How much does BioCryst Pharmaceuticals receive in federal contracts?

    BioCryst Pharmaceuticals had $36,032 in federal contract obligations over the 12 months through Jul 31, 2026, compared with -$26.87M in the 12 months before. Obligations are contract bookings by the awarding agency, not recognized revenue.

    What are BioCryst Pharmaceuticals' largest government contracts?

    The largest new awards over the 12 months through Jul 31, 2026 were 36C26026F0006, Department of Veterans Affairs, $360,000, started Oct 1, 2025; 36C26026F0294, Department of Veterans Affairs, $151,465, started May 19, 2026; 36C24926F0152, Department of Veterans Affairs, $30,293, started May 21, 2026.

    Which agencies award BioCryst Pharmaceuticals contracts?

    Department of Veterans Affairs was its only awarding agency over the 12 months through Jul 31, 2026.

    What new federal contracts did BioCryst Pharmaceuticals win in the 12 months through Jul 31, 2026?

    BioCryst Pharmaceuticals won 3 new federal contracts in the 12 months through Jul 31, 2026. The largest was 36C26026F0006, Department of Veterans Affairs, $360,000, started Oct 1, 2025.

    How do BioCryst Pharmaceuticals' federal obligations compare with its revenue?

    Federal contract obligations were $36,032 over the 12 months through Jul 31, 2026, equivalent to less than 1% of BioCryst Pharmaceuticals' revenue. Obligations are amounts the government committed to contracts in the period, not the share of BioCryst Pharmaceuticals' revenue that comes from the government.